Ackermans & van Haaren: Another Delen Private Bank acquisition in the Netherlands. Ahold Delhaize: Peer Albertsons FY24/25 results. ASML: 1Q25 results; already weaker ahead of the tariffs. Barco: Calm before the storm. Heineken: In the hold. Melexis: Partial move to China. Staffing sector: Hays' 3Q24/25 trading update; in line. Vopak: New industrial terminal or energy transition facility? WDP: €60m investment with KDL
Barco had a solid 1Q25 with y/y growth in each of its divisions. On the outlook, Barco indicated that the US tariffs are causing disruptions in global markets and supply chains, leading to reduced visibility and increased uncertainty. Barco has indicated that it is actively taking steps to protect its margins and market shares. However, Barco also highlighted that the impact on customer demand and investment decisions remains unpredictable. 1Q25 results were in line with Barco's own expectations...
DEME Group: Does money make life beautiful? Yes! Euronext: March Madness hits Markets. Kinepolis: Cineplex March 2025 box office revenue at 47% of 2019 level, down 50% YoY. Page Group: 1Q25 trading update; FY25 outlook more uncertain. SBM Offshore: Interesting step, but is it necessary? Staffing: French staffing: ongoing weak volumes in February on tough comps. WDP: €107m of new pre-let development projects
Trumps reciprocal tariffs caused a massive blow to equity markets, following a pressured period of escalating trade wars. Retaliatory measures can further heavily damage market confidence, as seen Friday when China announced their 34% tarrif of US goods. International trade policies have never moved this erratic and untransparant, with uncertainty and volatility being the baseline for now. In this report we highlight the key stocks in our coverage relevant to this discussion.
MaaT announced the positive outcome of a key DSMB safety interim analysis for the phase 2b trial (PHOEBUS), which compares the efficacy and safety of MaaT033 (microbiome therapy, oral capsule) to placebo in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT). We are encouraged by the DSMB outcome, particularly in the context that allo-HSCT is a high risk patient population, and see this as supportive of MaaT033´s good safety profile. We note that MaaT033 is next...
Today NX Filtration is hosting an in person CMD at its Hengelo HQ which we are attending. At the event the company will present its strategy to drive growth and its new medium-term objectives. The FY25 guidance calling for revenues growing 50-70% was reconfirmed but no financial insight into recent contract wins or 1Q25 revenues was given. The medium-term targets call for an EBITDA break-even but a more precise timing is not shared and likely to be clarified at the event. We currently bank on EB...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.